Tuzcu, S.Durmaz, S. A.Carlioglu, A.Demircan, Z.Tuzcu, A.Beyaz, C.Tay, A.2024-04-242024-04-2420170340-18551435-1250https://doi.org/10.1007/s00393-016-0171-6https://hdl.handle.net/11468/14414Objective. Growth hormone (GH) and insulinlike growth factor-1 (IGF-1) play a major role in bone homeostasis. In this study, we aimed to assess bone mineral density (BMD) in active acromegaly. Materials andmethods. A total of 29 patients with active acromegaly (age 46.10 +/- 13.27 years; body mass index [BMI]: 29.51 +/- 4.91 kg/m(2)) and 42 healthy individuals matched for age and BMI (age: 40.35 +/- 11.74 years; BMI: 28.18 +/- 7.35 kg/m(2)) were included in the study. BMD wasmeasured by DXA. Results. The mean levels of GH and IGF1 were found to be 12.61 +/- 11.34 ng/ml and 676.47 +/- 316.19 ng/ml in acromegaly, respectively, while the mean levels of GH and IGF-1 were found to be 0.59 +/- 0.81 ng/ml (p = 0.0001) and 178.17 +/- 57.11 ng/ml (p = 0.0001) in the control group, respectively. Only total hip t-score was determined to be significantly lower in acromegaly compared to the control group (p = 0.037). No significant differences were found between the other parameters in DXA and only a positive correlation was found between IGF-1 levels and L1-L4 BMD (r = 0.259, p = 0.029). Conclusions. Although GH and IGF-1 levels were increased in acromegalic patients, no significant difference was found in terms of vertebral BMD. Only hip t-scores were found to be lower in acromegalic patients, but this low hip t-score did not reach the osteopenic level. The positive correlation between IGF-1 and lumbar vertebral BMD suggested a more prominent effect of IGF-1 on BMD compared to GH.eninfo:eu-repo/semantics/closedAccessAcromegalyBone Mineral DensityInsulin Like Growth Factor-1 (Igf-1)Article768716722WOS:0004121683000142-s2.0-849917590052776641810.1007/s00393-016-0171-6Q3Q4